The 20 stocks most shorted by hedge funds
Seeking Alpha News (Wed, 14-Jan 7:29 AM ET)
Notable healthcare headlines for the week: AbbVie, UnitedHealth, and Novo Nordisk in focus
Seeking Alpha News (Sun, 11-Jan 9:05 AM ET)
Tolion Health AI Appoints Global Health & AI Leader Gregory J. Moore, MD, PhD, to Board of Directors
Business Wire (Tue, 6-Jan 6:00 AM ET)
DaVita Names New Leaders to Accelerate Care Transformation
PRNewswire (Thu, 11-Dec 8:00 AM ET)
DaVita Inc. to Participate in Fireside Chat with Wolfe Research
PRNewswire (Fri, 14-Nov 4:17 PM ET)
DaVita Marks 25 Years of Innovation with Breakthrough Kidney Care Research at ASN Kidney Week 2025
PRNewswire (Tue, 4-Nov 8:01 AM ET)
DaVita Inc. 3rd Quarter 2025 Results
PRNewswire (Wed, 29-Oct 4:06 PM ET)
DaVita Leads the Way in Evaluating Middle Molecule Clearance with Two New Initiatives
PRNewswire (Mon, 20-Oct 8:00 AM ET)
Is DVA stock going up before upcoming earnings? Let's turn to history for clues
Market Chameleon (Thu, 8-Feb 6:05 AM ET)
A Stock Rise in DVA has History on Its Side
Market Chameleon (Wed, 7-Feb 5:19 AM ET)
DaVita is the largest provider of dialysis services in the United States, boasting market share of about 35% when measured by clinics. The firm operates over 3,000 facilities worldwide, mostly in the US, and treats about 280,000 patients globally each year. Government payers dominate US dialysis reimbursement. DaVita receives about two thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business. Berkshire Hathaway owns about 45% of DaVita.
Davita trades on the NYSE stock market under the symbol DVA.
As of January 14, 2026, DVA stock price declined to $102.67 with 442,120 million shares trading.
DVA has a beta of 0.36, meaning it tends to be less sensitive to market movements. DVA has a correlation of 0.05 to the broad based SPY ETF.
DVA has a market cap of $7.25 billion. This is considered a Mid Cap stock.
Last quarter Davita reported $3 billion in Revenue and $2.51 earnings per share. This fell short of revenue expectation by $-716,348 and missed earnings estimates by -$.71.
In the last 3 years, DVA traded as high as $179.60 and as low as $71.51.
The top ETF exchange traded funds that DVA belongs to (by Net Assets): RSP, VTI, VOO, VB, VBR.
DVA has underperformed the market in the last year with a price return of -34.6% while the SPY ETF gained +19.6%. DVA has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -17.1% and -9.8%, respectively, while the SPY returned +4.1% and +0.2%, respectively.
DVA support price is $102.57 and resistance is $106.37 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that DVA shares will trade within this expected range on the day.